Margaret Jackson, PhD

Dr. Jackson is the founder and CEO of BYOMass and has successfully raised $15M. She is an experienced drug developer and neuropharmacology leader with >20 yrs of drug discovery/development expertise. Previously she was VP Preclinical R&D for Juvenescence and served on the Cardiovascular/Metabolic Disease Research Unit (CVMET) leadership team at Pfizer, where she built and led the CNS metabolic research team. She has a successful track record of initiating and developing small molecule and biologic programs from idea to Phase II clinical studies across 6 disease areas. She served on the Emerging Science and Technology Fund committee within Pfizer, responsible for assessing external scientific collaborations and seed investments across CVMET, Oncology, Inflammation/Immunology, Neuroscience, Chemistry, Biotherapeutics, Pharmaceutical Sciences and Drug Safety. Dr. Jackson received her D.Phil. from Oxford University and was awarded a Royal Society Fellowship.